Cancer Research Meeting Calendar EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rapisarda, A.
Right arrow Articles by Melillo, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rapisarda, A.
Right arrow Articles by Melillo, G.
[Cancer Research 62, 4316-4324, August 1, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

Identification of Small Molecule Inhibitors of Hypoxia-inducible Factor 1 Transcriptional Activation Pathway1

Annamaria Rapisarda2, Badarch Uranchimeg2, Dominic A. Scudiero, Mike Selby, Edward A. Sausville, Robert H. Shoemaker and Giovanni Melillo3

Developmental Therapeutics Program-Tumor Hypoxia Laboratory [A. R., B. U., G. M.], Science Applications International Corporation-Frederick, Inc. [D. A. S., M. S.], and Developmental Therapeutics Program, National Cancer Institute at Frederick [E. A. S., R. H. S.], Frederick, Maryland 21702-1201

Hypoxia-inducible factor 1 (HIF-1) is a master regulator of the transcriptional response to oxygen deprivation. HIF-1 has been implicated in the regulation of genes involved in angiogenesis [e.g., vascular endothelial growth factor (VEGF) and inducible nitric oxide synthase] and anaerobic metabolism (e.g., glycolytic enzymes). HIF-1 is essential for angiogenesis and is associated with tumor progression. In addition, overexpression of HIF-1{alpha} has been demonstrated in many common human cancers. Therefore, HIF-1 is an attractive molecular target for development of novel cancer therapeutics. We have developed a cell-based high-throughput screen for the identification of small molecule inhibitors of the HIF-1 pathway. We have genetically engineered U251 human glioma cells to stably express a recombinant vector in which the luciferase reporter gene is under control of three copies of a canonical hypoxia-responsive element (U251-HRE). U251-HRE cells consistently expressed luciferase in a hypoxia- and HIF-1-dependent fashion. We now report the results of a pilot screen of the National Cancer Institute "Diversity Set," a collection of approximately 2000 compounds selected to represent the greater chemical diversity of the National Cancer Institute chemical repository. We found four compounds that specifically inhibited HIF-1-dependent induction of luciferase but not luciferase expression driven by a constitutive promoter. In addition, these compounds inhibited hypoxic induction of VEGF mRNA and protein expression in U251 cells. Interestingly, three compounds are closely related camptothecin analogues and topoisomerase (Topo)-I inhibitors. We show that concomitant with HIF-1 and VEGF inhibition, the activity of the Topo-I inhibitors tested is associated with induction of cyclooxygenase 2 mRNA expression. The luciferase-based high-throughput screen is a feasible tool for the identification of small molecule inhibitors of HIF-1 transcriptional activation. In addition, our results suggest that altered Topo-I function may be associated with repression of HIF-1-dependent induction of gene expression.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
T. Narita, S. Yin, C. F. Gelin, C. S. Moreno, M. Yepes, K.C. Nicolaou, and E. G. Van Meir
Identification of a Novel Small Molecule HIF-1{alpha} Translation Inhibitor
Clin. Cancer Res., October 1, 2009; 15(19): 6128 - 6136.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
T. J. Waybright, J. R. Britt, and T. G. McCloud
Overcoming Problems of Compound Storage in DMSO: Solvent and Process Alternatives
J Biomol Screen, July 1, 2009; 14(6): 708 - 715.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Rapisarda, M. Hollingshead, B. Uranchimeg, C. A. Bonomi, S. D. Borgel, J. P. Carter, B. Gehrs, M. Raffeld, R. J. Kinders, R. Parchment, et al.
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
Mol. Cancer Ther., July 1, 2009; 8(7): 1867 - 1877.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Liu, C. K. Veena, J. B. Morgan, K. A. Mohammed, M. B. Jekabsons, D. G. Nagle, and Y.-D. Zhou
Methylalpinumisoflavone Inhibits Hypoxia-inducible Factor-1 (HIF-1) Activation by Simultaneously Targeting Multiple Pathways
J. Biol. Chem., February 27, 2009; 284(9): 5859 - 5868.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Pencreach, E. Guerin, C. Nicolet, I. Lelong-Rebel, A.-C. Voegeli, P. Oudet, A. K. Larsen, M.-P. Gaub, and D. Guenot
Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1{alpha} Axis
Clin. Cancer Res., February 15, 2009; 15(4): 1297 - 1307.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Zhang, D. Z. Qian, Y. S. Tan, K. Lee, P. Gao, Y. R. Ren, S. Rey, H. Hammers, D. Chang, R. Pili, et al.
Inaugural Article: Digoxin and other cardiac glycosides inhibit HIF-1{alpha} synthesis and block tumor growth
PNAS, December 16, 2008; 105(50): 19579 - 19586.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Puppo, F. Battaglia, C. Ottaviano, S. Delfino, D. Ribatti, L. Varesio, and M. C. Bosco
Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1{alpha} and -2{alpha}
Mol. Cancer Ther., July 1, 2008; 7(7): 1974 - 1984.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
R. R. Nair, H. Avila, X. Ma, Z. Wang, M. Lennartz, B. G. Darnay, D. D. Boyd, and C. Yan
A Novel High-Throughput Screening System Identifies a Small Molecule Repressive for Matrix Metalloproteinase-9 Expression
Mol. Pharmacol., March 1, 2008; 73(3): 919 - 929.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
X. Lin, C. A. David, J. B. Donnelly, M. Michaelides, N. S. Chandel, X. Huang, U. Warrior, F. Weinberg, K. V. Tormos, S. W. Fesik, et al.
A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation
PNAS, January 8, 2008; 105(1): 174 - 179.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Y. Koh, T. Spivak-Kroizman, S. Venturini, S. Welsh, R. R. Williams, D. L. Kirkpatrick, and G. Powis
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1{alpha}
Mol. Cancer Ther., January 1, 2008; 7(1): 90 - 100.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
A. Rapisarda and G. Melillo
HIF-1 Inhibitors: Novel Opportunities for Cancer Therapy
ASCO Educational Book, January 1, 2008; 2008(1): 543 - 547.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
S. Turcotte and A. J. Giaccia
Targeted Therapy for the Loss of the Tumor Suppressor Gene von Hippel-Lindau through Synthetic Lethality
ASCO Educational Book, January 1, 2008; 2008(1): e15 - e18.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
S. P. Manandhar, E. R. Hildebrandt, and W. K. Schmidt
Small-Molecule Inhibitors of the Rce1p CaaX Protease
J Biomol Screen, October 1, 2007; 12(7): 983 - 993.
[Abstract] [PDF]

Home page
 The OncologistHome page
M. O'Brien, J. Eckardt, and R. Ramlau
Recent Advances with Topotecan in the Treatment of Lung Cancer
Oncologist, October 1, 2007; 12(10): 1194 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. C. Land and A. R. Tee
Hypoxia-inducible Factor 1{alpha} Is Regulated by the Mammalian Target of Rapamycin (mTOR) via an mTOR Signaling Motif
J. Biol. Chem., July 13, 2007; 282(28): 20534 - 20543.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. S. Schwartz, M. K. Manion, C. B. Emerson, J. S. Fry, C. M. Schulz, I. R. Sweet, and D. M. Hockenbery
2-Methoxy antimycin reveals a unique mechanism for Bcl-xL inhibition
Mol. Cancer Ther., July 1, 2007; 6(7): 2073 - 2080.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. D. Sutphin, D. A. Chan, J. M. Li, S. Turcotte, A. J. Krieg, and A. J. Giaccia
Targeting the Loss of the von Hippel-Lindau Tumor Suppressor Gene in Renal Cell Carcinoma Cells
Cancer Res., June 15, 2007; 67(12): 5896 - 5905.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. A. Rempe, K. M. Lelli, G. Vangeison, R. S. Johnson, and H. J. Federoff
In Cultured Astrocytes, p53 and MDM2 Do Not Alter Hypoxia-inducible Factor-1{alpha} Function Regardless of the Presence of DNA Damage
J. Biol. Chem., June 1, 2007; 282(22): 16187 - 16201.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. L. Gillespie, K. Whang, B. T. Ragel, J. R. Flynn, D. A. Kelly, and R. L. Jensen
Silencing of Hypoxia Inducible Factor-1{alpha} by RNA Interference Attenuates Human Glioma Cell Growth In vivo
Clin. Cancer Res., April 15, 2007; 13(8): 2441 - 2448.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Creighton-Gutteridge, J. H. Cardellina II, A. G. Stephen, A. Rapisarda, B. Uranchimeg, K. Hite, W. A. Denny, R. H. Shoemaker, and G. Melillo
Cell Type-Specific, Topoisomerase II-Dependent Inhibition of Hypoxia-Inducible Factor-1{alpha} Protein Accumulation by NSC 644221
Clin. Cancer Res., February 1, 2007; 13(3): 1010 - 1018.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Iliopoulos
Molecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets
J. Clin. Oncol., December 10, 2006; 24(35): 5593 - 5600.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. Patiar and A. L Harris
Role of hypoxia-inducible factor-1{alpha} as a cancer therapy target
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S61 - S75.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Q. Ke and M. Costa
Hypoxia-Inducible Factor-1 (HIF-1)
Mol. Pharmacol., November 1, 2006; 70(5): 1469 - 1480.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Z. Qian, S. K. Kachhap, S. J. Collis, H. M.W. Verheul, M. A. Carducci, P. Atadja, and R. Pili
Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1{alpha}
Cancer Res., September 1, 2006; 66(17): 8814 - 8821.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
G. M. Woldemichael, J. R. Vasselli, R. S. Gardella, T. C. Mckee, W. M. Linehan, and J. B. McMahon
Development of a Cell-Based Reporter Assay for Screening of Inhibitors of Hypoxia-Inducible Factor 2-Induced Gene Expression
J Biomol Screen, September 1, 2006; 11(6): 678 - 687.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. T. Jones and A. L. Harris
Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding.
Mol. Cancer Ther., September 1, 2006; 5(9): 2193 - 2202.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Hussein, E. J. Estlin, C. Dive, and G. W.J. Makin
Chronic hypoxia promotes hypoxia-inducible factor-1{alpha}-dependent resistance to etoposide and vincristine in neuroblastoma cells.
Mol. Cancer Ther., September 1, 2006; 5(9): 2241 - 2250.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
G. Melillo
Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy
Mol. Cancer Res., September 1, 2006; 4(9): 601 - 605.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
W. Wang, S.-H. Kim, and W. S. El-Deiry
Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts
PNAS, July 18, 2006; 103(29): 11003 - 11008.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Melillo and G. L. Semenza
Meeting Report: Exploiting the Tumor Microenvironment for Therapeutics.
Cancer Res., May 1, 2006; 66(9): 4558 - 4560.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Nakamura, K. C. Martin, J. K. Jackson, K. Beppu, C.-W. Woo, and C. J. Thiele
Brain-Derived Neurotrophic Factor Activation of TrkB Induces Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Factor-1{alpha} in Neuroblastoma Cells.
Cancer Res., April 15, 2006; 66(8): 4249 - 4255.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Calvani, A. Rapisarda, B. Uranchimeg, R. H. Shoemaker, and G. Melillo
Hypoxic induction of an HIF-1{alpha}-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells
Blood, April 1, 2006; 107(7): 2705 - 2712.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
L. M. Brown, R. L. Cowen, C. Debray, A. Eustace, J. T. Erler, F. C. D. Sheppard, C. A. Parker, I. J. Stratford, and K. J. Williams
Reversing Hypoxic Cell Chemoresistance in Vitro Using Genetic and Small Molecule Approaches Targeting Hypoxia Inducible Factor-1
Mol. Pharmacol., February 1, 2006; 69(2): 411 - 418.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Lu, C. L. Dalgard, A. Mohyeldin, T. McFate, A. S. Tait, and A. Verma
Reversible Inactivation of HIF-1 Prolyl Hydroxylases Allows Cell Metabolism to Control Basal HIF-1
J. Biol. Chem., December 23, 2005; 280(51): 41928 - 41939.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Kong, E. J. Park, A. G. Stephen, M. Calvani, J. H. Cardellina, A. Monks, R. J. Fisher, R. H. Shoemaker, and G. Melillo
Echinomycin, a Small-Molecule Inhibitor of Hypoxia-Inducible Factor-1 DNA-Binding Activity
Cancer Res., October 1, 2005; 65(19): 9047 - 9055.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Hose, G. Kaur, E. A. Sausville, and A. Monks
Transcriptional Profiling Identifies Altered Intracellular Labile Iron Homeostasis as a Contributing Factor to the Toxicity of Adaphostin: Decreased Vascular Endothelial Growth Factor Secretion Is Independent of Hypoxia-Inducible Factor-1 Regulation
Clin. Cancer Res., September 1, 2005; 11(17): 6370 - 6381.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. W. Nelson, H. Cao, Y. Zhu, B. Sunar-Reeder, C. Y.H. Choi, J. D. Faix, J. M. Brown, A. C. Koong, A. J. Giaccia, and Q.-T. Le
A Noninvasive Approach for Assessing Tumor Hypoxia in Xenografts: Developing a Urinary Marker for Hypoxia
Cancer Res., July 15, 2005; 65(14): 6151 - 6158.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
E. W. Newcomb, M. A. Ali, T. Schnee, L. Lan, Y. Lukyanov, M. Fowkes, D. C. Miller, and D. Zagzag
Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1{alpha} expression in human glioma cells by a proteasome-independent pathway: Implications for in vivo therapy
Neuro-oncol, July 1, 2005; 7(3): 225 - 235.
[Abstract] [PDF]

Home page
 Mol. Cell. Biol.Home page
R. R. Raval, K. W. Lau, M. G. B. Tran, H. M. Sowter, S. J. Mandriota, J.-L. Li, C. W. Pugh, P. H. Maxwell, A. L. Harris, and P. J. Ratcliffe
Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma
Mol. Cell. Biol., July 1, 2005; 25(13): 5675 - 5686.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N.-M. Chau, P. Rogers, W. Aherne, V. Carroll, I. Collins, E. McDonald, P. Workman, and M. Ashcroft
Identification of Novel Small Molecule Inhibitors of Hypoxia-Inducible Factor-1 That Differentially Block Hypoxia-Inducible Factor-1 Activity and Hypoxia-Inducible Factor-1{alpha} Induction in Response to Hypoxic Stress and Growth Factors
Cancer Res., June 1, 2005; 65(11): 4918 - 4928.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M.-G. Song, S.-M. Gao, K.-M. Du, M. Xu, Y. Yu, Y.-H. Zhou, Q. Wang, Z. Chen, Y.-S. Zhu, and G.-Q. Chen
Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase C{delta}-dependent mechanisms
Blood, May 1, 2005; 105(9): 3714 - 3721.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
M. G. Hollingshead, J. P. Carter, K. Dougherty, and C. A. Bonomi
The Hollow Fiber Assay in Cancer Efficacy Testing in the Developmental Therapeutics Program at the National Cancer Institute
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 351 - 354.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Rapisarda, J. Zalek, M. Hollingshead, T. Braunschweig, B. Uranchimeg, C. A. Bonomi, S. D. Borgel, J. P. Carter, S. M. Hewitt, R. H. Shoemaker, et al.
Schedule-dependent Inhibition of Hypoxia-inducible Factor-1{alpha} Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts
Cancer Res., October 1, 2004; 64(19): 6845 - 6848.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
A. J. Giaccia, M. C. Simon, and R. Johnson
The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease
Genes & Dev., September 15, 2004; 18(18): 2183 - 2194.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. M. Linehan, J. Vasselli, R. Srinivasan, M. M. Walther, M. Merino, P. Choyke, C. Vocke, L. Schmidt, J. S. Isaacs, G. Glenn, et al.
Genetic Basis of Cancer of the Kidney: Disease-Specific Approaches to Therapy
Clin. Cancer Res., September 15, 2004; 10(18): 6282S - 6289S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. G. Kaelin Jr.
The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
Clin. Cancer Res., September 15, 2004; 10(18): 6290S - 6295S.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Kaufman, O. Scharf, J. Arbeit, M. Ashcroft, J. M. Brown, R. K. Bruick, J. D. Chapman, S. M. Evans, A. J. Giaccia, A. L. Harris, et al.
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting
Cancer Res., May 1, 2004; 64(9): 3350 - 3356.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. Powis and L. Kirkpatrick
Hypoxia inducible factor-1{alpha} as a cancer drug target
Mol. Cancer Ther., May 1, 2004; 3(5): 647 - 654.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Rapisarda, B. Uranchimeg, O. Sordet, Y. Pommier, R. H. Shoemaker, and G. Melillo
Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1: Mechanism and Therapeutic Implications
Cancer Res., February 15, 2004; 64(4): 1475 - 1482.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. C. Bosco, M. Puppo, S. Pastorino, Z. Mi, G. Melillo, S. Massazza, A. Rapisarda, and L. Varesio
Hypoxia Selectively Inhibits Monocyte Chemoattractant Protein-1 Production by Macrophages
J. Immunol., February 1, 2004; 172(3): 1681 - 1690.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. Huang, S. Z. Soffer, E. S. Kim, K. W. McCrudden, J. Huang, T. New, C. A. Manley, W. Middlesworth, K. O'Toole, D. J. Yamashiro, et al.
Vascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis
Mol. Cancer Res., January 1, 2004; 2(1): 36 - 42.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
T. Schioppa, B. Uranchimeg, A. Saccani, S. K. Biswas, A. Doni, A. Rapisarda, S. Bernasconi, S. Saccani, M. Nebuloni, L. Vago, et al.
Regulation of the Chemokine Receptor CXCR4 by Hypoxia
J. Exp. Med., November 3, 2003; 198(9): 1391 - 1402.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. A. Sosman
Targeting of the VHL-Hypoxia-Inducible Factor-Hypoxia-Induced Gene Pathway for Renal Cell Carcinoma Therapy
J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2695 - 2702.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
G. Petrangolini, G. Pratesi, M. De Cesare, R. Supino, C. Pisano, M. Marcellini, V. Giordano, D. Laccabue, C. Lanzi, and F. Zunino
Antiangiogenic Effects of the Novel Camptothecin ST1481 (Gimatecan) in Human Tumor Xenografts
Mol. Cancer Res., October 1, 2003; 1(12): 863 - 870.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. R. Macpherson, S. S.W. Ng, S. L. Forbes, G. Melillo, T. Karpova, J. McNally, T. P. Conrads, T. D. Veenstra, A. Martinez, F. Cuttitta, et al.
Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay
Mol. Cancer Ther., September 1, 2003; 2(9): 845 - 854.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. T. Palayoor, P. J. Tofilon, and C. N. Coleman
Ibuprofen-mediated Reduction of Hypoxia-inducible Factors HIF-1{alpha} and HIF-2{alpha} in Prostate Cancer Cells
Clin. Cancer Res., August 1, 2003; 9(8): 3150 - 3157.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Fukuda, B. Kelly, and G. L. Semenza
Vascular Endothelial Growth Factor Gene Expression in Colon Cancer Cells Exposed to Prostaglandin E2 Is Mediated by Hypoxia-inducible Factor 1
Cancer Res., May 1, 2003; 63(9): 2330 - 2334.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. Pili and R. C. Donehower
Is HIF-1{alpha} a Valid Therapeutic Target?
J Natl Cancer Inst, April 2, 2003; 95(7): 498 - 499.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Krishnamachary, S. Berg-Dixon, B. Kelly, F. Agani, D. Feldser, G. Ferreira, N. Iyer, J. LaRusch, B. Pak, P. Taghavi, et al.
Regulation of Colon Carcinoma Cell Invasion by Hypoxia-Inducible Factor 1
Cancer Res., March 1, 2003; 63(5): 1138 - 1143.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.